Drug Companies’ Lobbyist May Push to Expand U.S. Payments

Drugmakers may push to boost U.S. government spending on prescription drugs even as the U.S. Congress seeks to reduce health-care spending, according to internal documents from the industry’s top lobbying group.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.